Meeting
2012 Gastrointestinal Cancers Symposium
Single-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC).
Authors
Krishna Soujanya Gunturu
Yale University School of Medicine, New Haven, CT
Krishna Soujanya Gunturu , Jaykumar Ranchodbhai Thumar , Howard S. Hochster , Stacey Stein , Xiaopan Yao , Xiangyu Cong , Carol Hahn , Kristin Kaley , Jill Lacy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 30, 2012 (suppl 4; abstr 330)
DOI
10.1200/jco.2012.30.4_suppl.330
Abstract #
330
Poster Bd #
E14
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies.
First Author: Manish Sharma
Poster
2015 Gastrointestinal Cancers Symposium
Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC).
First Author: Edward Samuel James
Poster
2014 Gastrointestinal Cancers Symposium
Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).
First Author: Edward Samuel James
Poster
2019 Gastrointestinal Cancers Symposium
FOLFIRINOX in pancreatic cancer patients age 75 years or older.
First Author: Jonathan Mizrahi